Online Program

Return to main conference page
Thursday, September 13
Thu, Sep 13, 2:45 PM - 4:00 PM
Thurgood Marshall North
Advances and Application of Multiplicity Methods in Confirmatory Clinical Trials

Multiplicity for a Group Sequential Trial with Biomarker Subpopulations (300785)

*Jing Zhao, Merck 

The conventional design with only one primary study population (an overall population) has recently been challenged), particularly when the disease (e.g. cancer) is heterogeneous due to observable clinical characteristics and/or unobservable underlying biologic/genomic characteristics. In recent oncology clinical trials, biomarker subpopulations (biomarker +/-) have become increasingly important for drug development in tailored therapies to fulfill regulatory commitments. It is also desirable to optimize the study design to have a more enhanced claim in which multiple objectives can be met. In this work, we propose to extend the classical group sequential design set-up to the above setting and develop the methods and calculation with less conservative bounds and, therefore, a smaller required sample size or greater power.